In 2001, an international surveillance initiative was established, utilising a validated larval development inhibition assay to track the susceptibility of cat flea isolates to imidacloprid. In 2009, an Australian node was incorporated into the programme, joining laboratories in the United States and Europe. Field isolates of Ctenocephalides felis eggs were submitted to participating laboratories and, where egg quantity and quality was sufficient, were placed in the imidacloprid discriminating dose bioassay for evaluation. Between 2002 and 2012, a total of 2,307 cat flea isolates were received across all sites; 1,685 submissions (73 %) were suitable for placement into the bioassay. In the Northern Hemisphere, isolate submission rate was influenced by season, with highest numbers submitted
Introduction
The cat flea, Ctenocephalides felis felis, is widely recognised as the most common ectoparasite infesting dogs and cats worldwide (Bond et al. 2007; Rust 2005; Slapeta et al. 2011) . Aside from being a prominent cause of dermatitis and anaemia in these companion animals (reviewed by Dryden 2009), the cat flea is also a recognised vector for several disease agents, including Bartonella and Rickettsia spp. (Bitam et al. 2010) , feline calicivirus (Mencke et al. 2009 ) and feline leukaemia virus (Vobis et al. 2003 (Vobis et al. , 2005 . The subcutaneous filarial nematode Dipetalonema reconditum and the flea tapeworm Dipylidium caninum are also dependent upon the cat flea as an intermediate host (reviewed by Mehlhorn 2012) . The fact that C. felis vectors at least three zoonotic pathogens, Bartonella henselae, Rickettsia felis (Bitam et al. 2010) and Yersinia pestis (Mehlhorn 2012) , shines a spotlight on this parasite in the public health arena (Richter et al. 2002; Oteo et al. 2006; Mosbacher et al. 2010; Williams et al. 2011) . Given the close association between owners and their pets, it can be argued that flea control is important not only from a veterinary standpoint, but also as a protective measure for humans. Approaches to cat flea control have evolved considerably over time. Arguably the most significant change in the last twenty years has been a shift away from strategies that were underpinned by separate and often very frequent chemical treatment of host and environment, towards reliance upon monthly application of treatment to host only (Rust 2005) . This has been achieved thanks to the advent of several highly effective insecticide classes that maintain a high degree of residual adulticidal efficacy on the host and, in many cases, possess activity against off-host life stages in the host's environment (Dryden 2009 ). These newer actives, namely imidacloprid, fipronil, selamectin, dinotefuran and spinosad, have facilitated owner compliance by providing convenience. It must be acknowledged, however, that the desirable persistence of contemporary actives on the host is also a factor that renders potential vulnerability to the development of resistance. While no definitive evidence of high-level C. felis field resistance to the neonicotinoid, avermectin, spinosyn or phenylpyrazole classes has been published to date, Payne and colleagues (2001) have previously highlighted a flea isolate that showed reduced susceptibility to topical fipronil from 20 days post treatment. Dryden and colleagues (2005) observed a decline in topical imidacloprid efficacy on cats challenged with infestation 30 days post treatment. A study by Franc and Yao (2007) reported similar findings. It is not entirely clear whether the effective shortening of residual activity described in these reports reflects an absolute reduction in efficacy, or a reduced speed of kill (Kramer and Mencke 2001) . It is worth noting that imidacloprid has been demonstrated to have a rapid direct contact effect upon fleas, as opposed to actives such as fipronil and selamectin, which primarily require ingestion by fleas for pulicidal activity (Mehlhorn et al. 1999 (Mehlhorn et al. , 2001 ). Such differences in mode of action exert a profound effect upon speed of kill (Everett et al. 2000; Mehlhorn et al. 2001 ) and cautious interpretation is therefore required when comparing different actives under in vivo conditions. What is also unclear is how often suspect flea isolates, rarely reported in the literature, actually occur in the field, and whether such isolates are truly representative of the systematic development of resistance, or merely a reflection of the biological variability that might be expected in different flea populations (Kramer and Mencke 2001) . Given the extensive global use of modern monthly adulticides against C. felis, a handful of suspect isolate responses identified in the literature should not be cause for undue alarm. It is, however, worth noting the well-documented historical development of high-level field resistance to predecessor insecticide classes utilised in flea control, including the synthetic pyrethroids, carbamates and organophosphates (Rust and Dryden 1997) . Driven largely by the recognised need to make more judicious use of newer insecticides has been the adoption of an integrated flea control (IFC) approach, which was borne out of the integrated pest management (IPM) concept first pioneered in the agricultural sector (Kogan 1998) . The IFC approach advocates client education around flea biology, and reinforcement of adulticidal therapy by concurrent administration of insect growth regulators (IGRs) and employment of mechanical control practices such as regular vacuuming of the environment and use of flea traps (Dryden and Broce 2002) . A central tenant of integrated pest management is 'monitoring' (Abrol and Shankar 2012) . While this component of IPM traditionally refers to monitoring of pest levels in the environment as a means to inform strategic control practices, it stands to reason that this rationale should extend to surveillance around the development of insecticide resistance in pest populations. To this end, an intensive C. felis imidacloprid susceptibility monitoring initiative was established in 1999, comprising an international group of collaborating laboratories. The basis of the monitoring undertaken by this group is a validated imidacloprid larval development inhibition assay (Rust et al. 2002) , for which a diagnostic dose (DD) has been determined to facilitate applicability to high-throughput field isolate screening . While the concept of utilising laboratory bioassays for monitoring parasiticide responses is not novel, the geographic scope, high degree of co-ordination and longevity of this monitoring initiative make it unique, particularly within the field of veterinary parasitology. With the programme entering its twelfth year of formal operations, it is timely to review the data generated by this work and to reflect upon lessons learned from the coordination and evolution of a complex project across geographically dispersed laboratories on three continents.
Materials and methods

Field isolate sampling
Field isolates of flea eggs collected from veterinary clinics were submitted to participating parasitology laboratories in the United States (Auburn, Riverside, Kansas), Germany (Monheim), the United Kingdom (London) and Australia (Brisbane). Upon enrolment into the programme, participating clinics were supplied with a collection kit, comprising equipment and receptacles for flea egg collection, a detailed protocol and a questionnaire requesting information from the owner regarding their pet's signalment, flea preventative treatment history and pertinent details of the animal's environment, including the presence of other pets in the household (Blagburn et al. 2006; Rust et al. 2005) . Flea eggs were collected from patients identified to be carrying a flea burden according to the supplied protocol . Briefly, the animal was placed into an environment conducive to collection of flea eggs, typically a cage with mesh or grated floor, and provided with ad libitum water and access to food and litter trays as required. An appropriate collection medium, such as newspaper, was placed underneath the cage. Following a period of between 4 h and 24 h, the animal was gently but thoroughly combed in order to remove flea eggs from the pelage. Eggs and debris collected underneath the cage were then transferred to a glass collection tube by use of a supplied sieve and funnel. Where overnight shipping was required, tubes were packed into an appropriately insulated container; for shorter same-day shipping and where climatic conditions were not extreme, tubes were bubble-wrapped for protection and shipped in an envelope.
Diagnostic dose bioassays
Upon receipt of a field submission, the responsible laboratory assessed the submitted material for flea egg quantity using a dissecting microscope. Where flea egg quantity was sufficient to permit conduct of a diagnostic dose (DD) bioassay, this was performed in accordance with the protocol outlined by Rust and colleagues (2005) . Batches of 20 eggs were placed into glass Petri dishes containing either larval rearing media pre-treated to achieve a concentration of 3 ppm imidacloprid, or untreated media as a control. Up to six treated and three untreated replicates were prepared for each isolate where egg quantity permitted. As a further quality control measure, 20 eggs representative of in-house C. felis reference strains available at each site were placed on untreated media and incubated in parallel with the test isolate, in order to monitor conditions affecting hatchability. All dishes were incubated at 26 ± 2 °C and 80-85 % relative humidity. Dishes were inspected after 12 d incubation in order to quantify larvae and pupae, and again at 28 d to quantify emerged adults.
Debris testing
Where no egg hatch was observed in untreated replicates, and sufficient debris was present in the submitted material, a debris test was performed to screen for the presence of inhibitory residues.
As outlined by Rust and colleagues (2011) , this procedure entailed incubation of 20 control strain eggs with the debris (26 ± 2 °C and 80-85 % relative humidity). Failure of any control eggs to hatch and develop to adults after 28 d incubation was considered to indicate the presence of an inhibitory residue in the submission.
Repeat diagnostic dose bioassays
If 5 % or greater adult emergence was observed at the 3 ppm DD imidacloprid concentration, emerged adult fleas in the untreated control dishes were retained and placed on a cat in order to propagate the isolate. Where any participating laboratories did not have access to cats for propagation, pupae were promptly shipped to the nearest laboratory with this capacity. Following propagation, flea eggs were collected from the cat as previously described and a repeat 3 ppm imidacloprid DD bioassay was undertaken on three replicates of 20 eggs. At least one untreated control replicate was also setup in parallel. Emerged adult fleas were quantified in all dishes after 28 d incubation.
Full-dose bioassays and probit analysis
Field submissions with 5 % or greater adult emergence in both preliminary and repeat DD bioassay testing were designated as isolates of interest. These isolates were further propagated on cats, and eggs were collected for use in full-dose response bioassays, conduct of which has been previously described (Rust et al. 2011) . Briefly, larval rearing medium was treated to achieve a gradient of nine imidacloprid concentrations (0.005, 0.01, 0.05, 0.1, 0.3, 0.5, 1, 1.5 and 3 ppm). Twenty flea eggs were added to each dish, however a slight modification for the full-dose bioassays was that eggs were not directly added to the media, but were instead carefully glued (UHU adhesive, Saunders Co., ME, USA) to the lid of each dish. This strategy sought to minimise impacts of cannibalism on egg hatch and larval development, given the higher degree of granularity sought from this level of testing. As for the DD bioassay, untreated media was used to monitor control mortality. Dishes were incubated at 26 ± 2 °C and 80-85 % relative humidity, with larvae and pupae counting at 12 d and quantification of emerged adults at 28 d. Dose response probit lines were generated using the POLO software package (Version 1.0, LeOra Software, Menlo Park, CA, USA), permitting calculation of dose response slope, LC 50 and LC 95 values.
Results
Field isolate sampling
While the programme was formally initiated in 2001, and 240 field isolates were submitted in this first year of operation, bioassay data was formally recorded and archived from 2002 onwards. Between January 2002 and December 2012, a total of 2,307 field isolates were received across all sites. This was represented by 1,516 isolates obtained from cats (approx. 66 %) and 770 isolates from dogs (approx. 33 %); a host species was not recorded for 21 submissions. An overview of submissions received across investigator sites is provided in Table 1 . Submissions in North America totalled 1,331, 840 were received across Europe and 136 were received in Australia. Egg numbers in each submission ranged from zero to greater than 5,000, although only 2 % of submissions contained more than 1,000 eggs. There was an average of 208 eggs per submission across the programme. In the Northern Hemisphere, which represents all sites outside of Australia, field isolate submission rate tended to peak between June and December, while submissions in the Southern Hemisphere (Australia) were highest between August and October.
Diagnostic dose bioassays
Of the 2,307 field isolates received between 2002 and 2012, 1,685 (73 %) were suitable for placement into the imidacloprid DD bioassay. The greatest factor rendering isolates unusable was insufficient flea egg numbers. Of the 1,685 bioassays performed, 1,367 (81 %) were valid as determined by hatching of at least one egg in control (untreated) media. The dorsal hind tibia of all emerging adults was examined and all specimens were consistent with C. felis and not the closely related species Ctenocephalides canis. Discriminating dose bioassays conducted between 2002 and 2012 exposed 95,729 individual C. felis eggs to the 3 ppm imidacloprid diagnostic dose. A total of 453 eggs (0.47 %), across 78 isolates, developed to adulthood. With respect to individual field submissions, flea emergence 5 % or greater at 3 ppm imidacloprid was observed in 38 of the 1,367 tested in valid DD bioassays (2.8 %) (Table 1) . No clear trends emerged with respect to either percentage egg emergence, which ranged yearly 
Repeat diagnostic dose bioassays and full-dose bioassays
Propagation of isolates reaching or exceeding the 5 % survivorship threshold in preliminary testing could not be achieved in many cases. Factors impeding propagation included submissions containing only enough eggs to run a single control replicate, resulting in few emerged adults, isolates for which control replicate hatchability was poor, isolates for which adults emerged from control media with poor fitness, and isolates that would not establish a fertile infestation even when apparently fit adult fleas were placed onto the pelage of a cat. In all cases where adequate propagation could be achieved, repeat diagnostic dose testing failed to identify any isolates that reached or exceeded the 5 % survivorship threshold a second time, implying that survival was a chance effect rather than indicating a systematic shift in susceptibility. While no isolates were deemed to require fulldose gradient profiling on the basis of reaching or exceeding the survivorship threshold in two consecutive DD bioassays, some isolates were selected to undergo full-dose testing on the basis of moderate to high emergence of adult fleas (generally above 10 %) in preliminary DD testing. Full-dose gradient profiling of these isolates is outlined in Table 2 . None of these isolates had observed slope, LC 50 or LC 95 characteristics that were appreciably different from the susceptible reference strains UCR, AUB and KS1.
Discussion
The imidacloprid susceptibility monitoring initiative reviewed in this paper represents the most ambitious and comprehensive surveillance project for any parasiticide in the veterinary sector. Over a period of twelve years, more than 1,300 individual cat flea isolates were screened with valid imidacloprid discriminating dose bioassays across three different continents. It is notable that just 0.47 % of all eggs assayed over this period developed to adult fleas in the presence of 3 ppm imidacloprid, and just 2.8 % of field isolates exceeded the diagnostic dose threshold. Crucially, none of these isolates reached or exceeded the 5 % survival threshold on repeat testing, hence they could not be characterised as possessing field resistance to imidacloprid. As commented an earlier review of this initiative (Rust et al. 2011) , it is likely that initial survivorship in the DD bioassay that cannot be replicated represents a chance finding, and not the systematic development of resistance in that population. It is worth reflecting upon data pertaining to the flea isolate submission process itself, since this can provide insight into seasonal prevalence of C. felis. In the Northern Hemisphere, sampling was undertaken year-round, with submission rate largely driven by the availability of fertile flea burdens yielding eggs. Unsurprisingly, viable submissions peaked during the warmer months between June and October, which is likely to represent the most active period for expansion of flea biomass within a household. However, as noted previously (Rust et al. 2011) , the programme has consistently received Northern Hemisphere submissions during winter months, albeit at a reduced rate. This finding advocates year-round treatment, particularly since winter flea burdens are likely to provide a strong impetus for a rise in flea numbers as warmer spring temperatures become more conducive to larval development. In Australia, submission rate was highly influenced by programme factors, since many isolates were sourced from patients admitted to a desexing clinic associated with that laboratory's institution. This clinic was most active between August and October each year, hence submission rate was strongest during this period. The fact that isolate sampling at the Australian node of the programme was largely sustained by submissions during late winter and early spring is testament to the need for year-round use of flea preventatives in this country also, where much of the population resides in subtropical or mildly temperate climatic zones. The incorporation of an Australian node in 2009 was an important means of expanding the geographic scope of the initiative. There were, however, significant challenges to be overcome in establishing a participating laboratory on this isolated island continent. Aside from the marked geographic separation of the Australian laboratory from those in the USA and Europe, increasing internationalisation of the initiative required significant co-ordination to achieve import and export of biological materials across international borders. Harmonisation of bioassay procedures has been an ongoing priority for the susceptibility monitoring team, a process that necessitates exchange of flea strains between laboratories. A primary goal upon establishment of the Australian node was shipment of a representative C. felis field isolate from that country for full-dose response profiling in collaborating international laboratories. The dose response characteristics of this isolate (AUS 1) were outlined in an earlier review of the initiative (Rust et al. 2011) ; it was determined to be phenotypically similar to the imidacloprid-susceptible reference strains UCR, KS1 and AUB. Profiling of this isolate was one step in a detailed series of laboratory visits, personnel training workshops and teleconferences that began as early as 2007. This comprehensive planning facilitated a relatively seamless entry of the Australian laboratory into the programme in 2009. Although only 97 Australian cat flea isolates have undergone valid DD bioassay testing to date, a reflection of the Australian laboratory's nascent participation and the considerably smaller population base in Australia as compared to North America and Europe, it is noteworthy that none of these isolates enabled 5 % or greater survivorship at 3 ppm imidacloprid. This uniform field susceptibility is consistent with the dose response profile of AUS 1, which showed remarkable similarity to (Rust et al. 2011) , this isolate was profiled as an exercise in bioassay harmonisation and not due to survivorship in the 3 ppm imidacloprid DD bioassay. Australia is a continent of unique isolation and biodiversity, where a rich agricultural heritage has seen widespread use of pesticides, notably persistent organic compounds such as dieldrin and DDT (Kausik 1991) . Although use of these compounds has now been banned in that country (Shivaramaiah et al. 2002) , background exposure of parasite populations to bioaccumulative compounds creates uncertainty around how such populations might respond over time to novel parasiticides, particularly where non-specific metabolic resistance mechanisms are possible. Superimposed on this is the high degree of treatment compliance seen in Australian pet owners (Schantz 1991) . While commendable, strong treatment compliance obviously drives selection for resistance. It is therefore heartening that, in the sixteen years since Hopkins and colleagues (1996) demonstrated high in-vivo efficacy of imidacloprid against a representative Australian C. felis isolate, there appears to have been no appreciable shift in imidacloprid susceptibility in that country.
In an earlier review, Rust and colleagues (2011) commented on a significant reduction in control hatchability of field isolates over the first seven years of the programme, a trend that has continued through 2012. As outlined previously, it is possible that this reduction is due to receipt of an increased number of samples contaminated by an IGR, reflecting increased market-share of combination adulticide-IGR flea control products. Driven by concerns around IGR contamination of field isolates, routine testing of debris from invalid DD bioassays has now been formally incorporated into the programme. In 2012, this testing revealed nil control strain egg hatch in debris from 67 % of invalid bioassays tested, suggesting IGR contamination in these submissions. While scrutinising debris with a control strain hatchability test is a useful preliminary screen for presence of inhibitory residues, it remains a somewhat blunt tool and requires that appreciable debris are present in submitted material. Given that invalid bioassays are a waste of physical and human resources, it would be useful to be able to identify a contaminated submission upon receipt, and to be able to determine the identity of any inhibitory residue present. This is increasingly possible as technology advances, but requires further investigation. A further challenge that has emerged more recently is the difficulty encountered in propagating isolates that exceed the survivorship threshold in preliminary imidacloprid DD screening. It is not clear whether this is related to any kind of fitness cost associated with reduced susceptibility to imidacloprid, because survivorship in preliminary 3 ppm DD bioassays is not definitive proof of imidacloprid tolerance. As previously discussed, all surviving isolates for which propagation was achieved did not survive subsequent 3 ppm imidacloprid exposure, and isolates for which full-dose response profiling was undertaken were comparable to susceptible reference strains. Fitness cost has been associated with imidacloprid resistance in crop pests (Baker et al. 2007; Liu and Han 2006) , however, it is too early to determine whether this might also occur in C. felis, particularly since no imidacloprid-tolerant strains have yet been identified. While failed propagation of interesting isolates is a frustration in one sense, there is also opportunity for investigation into why many of these isolates do not readily favour propagation. The longevity of this imidacloprid susceptibility monitoring initiative is testament to the high degree of cooperation between collaborating laboratories, and the sustained and valued contributions of the many veterinary clinics participating in the programme. Coordinated surveillance projects such as the one described in this paper are a crucial undertaking; it would be foolish to assume that modern flea adulticides are immune from resistance and even more foolish to expect that the golden age of parasiticide discovery enjoyed over the last 25 years will continue indefinitely. It is noteworthy, however, that in spite of scrutiny across three continents over an extended period, there continues to be an ongoing lack of C. felis field isolates showing resistance to imidacloprid. The adoption of integrated flea control practices is an excellent step that favours responsible insecticide use, however, these ideals must be reinforced by comprehensive surveillance using sensitive tools that are likely to detect emerging resistance long before it manifests as treatment failure in the field.
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